<DOC>
	<DOCNO>NCT01503385</DOCNO>
	<brief_summary>Concurrent chemoradiation ( ChRT ) standard care unresectable stage III non-small cell lung cancer ( NSCLC ) patient good performance status , cisplatin/etoposide ( EP ) regimen one commonly use regimen . However , prognosis patient still rather poor . It demonstrate Cyclooxygenase ( COX ) -2 play important role pathogenesis lung cancer . Selective ( COX ) -2 inhibitor promote chemosensitivity radiosensitivity tumor cell preclinical trial . This single-institution , open-label , randomized phase II trial celecoxib administer concurrently cisplatin , etoposide , radiation therapy patient locally advanced NSCLC , determine feasibility , activity , toxicity combination unresectable NSCLC , examine biomarkers predict response treatment .</brief_summary>
	<brief_title>Cisplatin/Etoposide Concurrent Radiotherapy With Without Celecoxib Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Celecoxib non-steroidal-anti-inflammatory drug ( NSAIDS ) Recent study show celecoxib antitumor activity , may increase tumor sensitivity radiation . Furthermore , evidence show safety efficiency celecoxib phase I/II study . The purpose study examine effect new combination celecoxib ( Celebrex® ) cisplatin/etoposide ( EP regimen ) , concurrent thoracic radiotherapy unresectable stage III NSCLC patient ; examine biomarkers predict response treatment . Because poor survival patient unresected locally advanced NSCLC , efficiency celecoxib plus concurrent EP chemoradiotherapy need investigate .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>• 1870 year old , male female Histological cytological evidence NSCLC . Unresectable Stage III NSCLC . Karnofsky score : least 70 . Estimated survival : least 6 month Not receive radiotherapy combine modality therapy treat another malignancy . No history active gastric ulcer , active GI bleeding , renal failure . No severe hypertension , cardiac disease , diabetes mellitus Normal blood routine chemical test Patients guardian must inform investigational nature study must sign give write informed consent accordance institutional federal guideline . • Other malignancy simultaneously except situ cervix nonmelanoma skin cancer Extensive distant metastasis Pregnancy lactation Allergic Sulfonamides , NSAIDS Celebrex Routine use NSAIDS high dose Aspirin History cardiovascular disease include : myocardial infraction , angina , coronary angioplasty , congestive heart failure , stroke , coronary bypass surgery last 6 month . Abnormal coagulation history deep venous thrombosis , pulmonary embolism , systemic lupus erythematous , family history protein S C deficiency , prior heparininduced thrombocytopenia , Factor V Leiden deficiency high homocysteine level .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Celecoxib</keyword>
	<keyword>phase II</keyword>
</DOC>